Javier San Martin
Chief Tech/Sci/R&D Officer chez ATHIRA PHARMA, INC.
Fortune : 6 M $ au 31/03/2024
Profil
Javier San Martin is currently the Chief Medical Officer at Athira Pharma, Inc. He previously worked as the Executive Director-Bone Therapeutic Area at Amgen, Inc., as a Principal at Eli Lilly & Co., and as the Chief Medical Officer at Arrowhead Pharmaceuticals, Inc. from 2019 to 2024.
Prior to that, he was the Senior VP & Head-Global Clinical Development at Ultragenyx Pharmaceutical, Inc. from 2013 to 2019, and the Senior Vice President-Clinical Development at Lundbeck Seattle BioPharmaceuticals, Inc. Dr. San Martin obtained his doctorate degree from the University of Buenos Aires School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/01/2024 | 198 497 ( 0,16% ) | 6 M $ | 31/03/2024 |
Postes actifs de Javier San Martin
| Sociétés | Poste | Début |
|---|---|---|
| ATHIRA PHARMA, INC. | Chief Tech/Sci/R&D Officer | 15/04/2024 |
Anciens postes connus de Javier San Martin
| Sociétés | Poste | Fin |
|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/11/2019 |
| AMGEN INC. | Corporate Officer/Principal | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Javier San Martin
| University of Buenos Aires School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| ARROWHEAD PHARMACEUTICALS, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
